Manufacturer of Controlled Substances; Notice of Application, 48944-48945 [E6-13840]
Download as PDF
<![CDATA[
48944
Federal Register / Vol. 71, No. 162 / Tuesday, August 22, 2006 / Notices
—Enhance the quality, utility, and
clarity of the information to be
collected; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
cprice-sewell on PROD1PC66 with NOTICES
Overview of This Information
Collection:
(1) Type of Information Collection:
Extension of a currently approved
collection.
(2) Title of the Form/Collection:
Annual Reporting Requirement for
Manufacturers of Listed Chemicals.
(3) Agency form number, if any and
the applicable component of the
Department sponsoring the collection:
Form number: none. Office of Diversion
Control, Drug Enforcement
Administration, U.S. Department of
Justice.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract: Primary: Business or other forprofit. Other: None. Abstract: This
information collection permits the Drug
Enforcement Administration to monitor
the volume and availability of
domestically manufactured listed
chemicals. These listed chemicals may
be subject to diversion for the illicit
production of controlled substances.
This information collection is required
by law.
(5) An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: It is estimated that there are
one hundred (100) total respondents for
this information collection. One
hundred (100) persons respond
annually at 4 hours per response.
(6) An estimate of the total public
burden (in hours) associated with the
collection: It is estimated that there are
400 annual burden hours associated
with this collection.
If additional information is required
contact: Lynn Bryant, Department
Clearance Officer, United States
Department of Justice, Justice
Management Division, Policy and
Planning Staff, Patrick Henry Building,
Suite 1600, 601 D Street, NW.,
Washington, DC 20530.
Dated: August 17, 2006.
Lynn Bryant,
Department Clearance Officer, U.S.
Department of Justice.
[FR Doc. E6–13908 Filed 8–21–06; 8:45 am]
BILLING CODE 4410–09–P
VerDate Aug<31>2005
15:34 Aug 21, 2006
Jkt 208001
DEPARTMENT OF JUSTICE
Drug
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 8, 2006,
Aldrich Chemical Company Inc., DBA
Isotec, 3858 Benner Road, Miamisburg,
OH 45342–4304, made application by
renewal, to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
of controlled substances listed in
Schedule I and II:
Drug
Schedule
Cathinone (1235) ..........................
Methcathinone (1237) ..................
N-Ethylamphetamine (1475) ........
N,N-Dimethylamphetamine (1480)
Aminorex (1585) ...........................
Gamma
hydroxybutyric
acid
(2010).
Methaqualone (2565) ...................
Ibogaine (7260) ............................
Lysergic acid dethylamide (7315)
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
2,5-Dimethoxyamphetamine
(7396).
3,4-Methylenedioxyamphetamine
(7400).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4-Methylenedioxy-methamphetamine (7405).
4-Methoxyamphetamine (7411) ...
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
N-Ethyl-1-phenylcyclohexylamine
(7455).
Dihydromorphine (9145) ...............
Normorphine (9313) .....................
Acetylmethadol (9601) .................
Alphacetylmethadol Except LevoAlphacetylmethadol (9603).
Normethadone (9635) ..................
Norpipanone (9636) .....................
3-Methylfentanyl (9813) ................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
1-Phenylcyclohexylamine (7460)
Phencyclidine (7471) ....................
Phenylacetone (8501) ..................
1Piperidinocyclohexanecarbonitrile (8603).
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Benzoylecgonine (9180) ...............
Ethylmorphine (9190) ...................
Hydrocodone (9193) .....................
Isomethadone (9226) ...................
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Meperidine (9230) ........................
Meperidine intermediate-A (9232)
Merperidine intermediate-B (9233)
Methadone (9250) ........................
Methadone intermediate (9254) ...
Dextropropoxyphene, bulk, (nondosage forms) (9273).
Morphine (9300) ...........................
Normorphine (9313) .....................
Thebaine (9333) ...........................
Levo-alphacetylmethadol (9648) ..
Oxymorphone (9652) ...................
Fentanyl (9801) ............................
Schedule
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
small quantities of the listed controlled
substances to produce isotope labeled
standards for drug testing and analysis.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, VA 22301; and must be
filed no later than October 23, 2006.
Dated: August 15, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–13849 Filed 8–21–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on April 25, 2006,
American Radiolabeled Chemicals, Inc.,
101 Arc Drive, St. Louis, Missouri
63146, made application by renewal,
and by correspondence dated June 2,
2006, to the Drug Enforcement
Administration (DEA) for registration as
a bulk manufacturer of the basic classes
of controlled substances listed in
Schedules I and II:
E:\FR\FM\22AUN1.SGM
22AUN1
48945
Federal Register / Vol. 71, No. 162 / Tuesday, August 22, 2006 / Notices
Drug
Schedule
Gamma
hydroxybutyric
acid
(2010).
Ibogaine (7260) .............................
Lysergic acid diethylamide (7315)
Tetrahydrocannabinols (7370) ......
Dimethyltryptamine (7435) ............
Dihydromorphine (9145) ...............
Amphetamine (1100) ....................
Methamphetamine (1105) .............
Amobarbital (2125) .......................
Phencyclidine (7471) ....................
Phenylacetone (8501) ...................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine(9120) ...................
Oxycodone (9143) ........................
Hydromorphone (9150) .................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Meperidine (9230) .........................
Metazocine (9240) ........................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ....................
Fentanyl (9801) .............................
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Drug
The company plans to manufacture
small quantities of the listed controlled
substances as radiolabeled compounds
for biochemical research.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than October 23, 2006.
Dated: August 15, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–13840 Filed 8–21–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
cprice-sewell on PROD1PC66 with NOTICES
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
VerDate Aug<31>2005
15:34 Aug 21, 2006
Jkt 208001
substance in Schedule I or II and prior
to issuing a registration under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on March
31, 2006, Applied Science Labs,
Division of Alltech Associates Inc., 2701
Carolean Industrial Drive, State College,
Pennsylvania 16801, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances listed in Schedule
I and II:
Schedule
Heroin (9200) ................................
Cocaine (9041) .............................
Codeine (9050) .............................
Meperidine (9230) .........................
Methadone (9250) ........................
Morphine (9300) ...........................
I
II
II
II
II
II
The company plans to import these
controlled substances for the
manufacture of reference standards.
Any manufacturer who is presently,
or is applying to be, registered with DEA
to manufacture such basic classes of
controlled substances may file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than September 21, 2006.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substances in Schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
Dated: August 15, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–13843 Filed 8–21–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on June 6, 2006,
Cambrex North Brunswick, Inc.,
Technology Centre of New Jersey, 661
Highway One, North Brunswick, NJ
08902, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in Schedule
I and II:
Drug
N-Ethylamphetamine (1475) .........
Tetrahydrocannabinols (7370) ......
2,5–Dimethoxyamphetamine
(7396).
3,4–Methylenedioxyamphetamine
(7400).
4–Methoxyamphetamine (7411) ...
Amphetamine (1100) ....................
Methamphetamine (1105) .............
Methylphenidate (1724) ................
Pentobarbital (2270) .....................
Phenylacetone (8501) ...................
Hydromorphone (9150) .................
Hydrocodone (9193) .....................
Methadone (9250) ........................
Methadone Intermediate (9254) ...
Morphine (9300) ...........................
Sufentanil (9740) ..........................
Fentanyl (9801) .............................
Schedule
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ ODL;
E:\FR\FM\22AUN1.SGM
22AUN1
]]>Agencies
[Federal Register Volume 71, Number 162 (Tuesday, August 22, 2006)]
[Notices]
[Pages 48944-48945]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-13840]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on April 25, 2006, American
Radiolabeled Chemicals, Inc., 101 Arc Drive, St. Louis, Missouri 63146,
made application by renewal, and by correspondence dated June 2, 2006,
to the Drug Enforcement Administration (DEA) for registration as a bulk
manufacturer of the basic classes of controlled substances listed in
Schedules I and II:
[[Page 48945]]
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Gamma hydroxybutyric acid (2010)............ I
Ibogaine (7260)............................. I
Lysergic acid diethylamide (7315)........... I
Tetrahydrocannabinols (7370)................ I
Dimethyltryptamine (7435)................... I
Dihydromorphine (9145)...................... I
Amphetamine (1100).......................... II
Methamphetamine (1105)...................... II
Amobarbital (2125).......................... II
Phencyclidine (7471)........................ II
Phenylacetone (8501)........................ II
Cocaine (9041).............................. II
Codeine (9050).............................. II
Dihydrocodeine(9120)........................ II
Oxycodone (9143)............................ II
Hydromorphone (9150)........................ II
Ecgonine (9180)............................. II
Hydrocodone (9193).......................... II
Meperidine (9230)........................... II
Metazocine (9240)........................... II
Morphine (9300)............................. II
Thebaine (9333)............................. II
Oxymorphone (9652).......................... II
Fentanyl (9801)............................. II
------------------------------------------------------------------------
The company plans to manufacture small quantities of the listed
controlled substances as radiolabeled compounds for biochemical
research.
Any other such applicant and any person who is presently registered
with DEA to manufacture such a substance may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or objections being sent via regular mail
should be addressed, in quintuplicate, to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, Washington, DC 20537, Attention: DEA Federal Register
Representative/ODL; or any being sent via express mail should be sent
to DEA Headquarters, Attention: DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must
be filed no later than October 23, 2006.
Dated: August 15, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E6-13840 Filed 8-21-06; 8:45 am]
BILLING CODE 4410-09-P
